top of page
Search

Is AxioMed the Tesla of Spine Devices ?

DoctorpreneurNews

Updated: 5 days ago

Tesla has no mechanical engine. AxioMed has no mechanical parts.

By Kingsley R. Chin, MD, MBA


Just as Tesla moved away from engines, AxioMed's viscoelastic disc replacement moves beyond pedicle screws, interbody cages, and bone grafts to closely mimic a natural disc and restore natural spine movement
Just as Tesla moved away from engines, AxioMed's viscoelastic disc replacement moves beyond pedicle screws, interbody cages, and bone grafts to closely mimic a natural disc and restore natural spine movement

Tesla Didn’t Just Build a Car—It Changed an Industry

Tesla didn’t become a trillion-dollar company by selling the most cars. It became one by eliminating the mechanical engine, proving that an entirely new approach can reshape an industry. Today, despite selling far fewer vehicles than Ford or GM, Tesla’s $1.31 trillion market cap far exceeds Ford’s $40.22 billion and GM’s $49.19 billion.

 

Tesla’s success proves a simple but powerful truth: 10x advanced technology that redefines an industry creates enormous value, regardless of unit sales.

 

Now, that same transformation is happening in spine surgery, and AxioMed is leading the way.


 

The Next Big 10x Advancement in Spine Surgery

Legacy spine companies have built billion-dollar businesses around spinal fusion, relying on commoditized technologies such as pedicle screws, interbody cages, and bone grafts to immobilize the spine. While these companies offer cervical disc replacements, their designs are mechanical, functioning more like total knee replacements rather than truly preserving natural spinal motion.

 

Notably, they have no lumbar disc replacement. Instead of developing 10x technology, these companies focus on consolidation and acquisitions to expand market share—Medtronic’s Cranial and Spinal Technologies (CST) division generated $3.38 billion in FY2024 (1), and Globus Medical reached $2.52 billion (2).


"According to Medtronic, the combination of differentiated implants, biologics and technology is a winning formula in the spine market. Company CEO Geoffrey Martha said that technology is changing the competitive landscape of the spine market" (1)—yet their advancements in spine could be considered incremental rather than transformative.


Over $90 million has been raised to bring AxioMed to this pivotal stage, supported by 10+ years of clinical outcomes as proof. We are now closing the final $10 million of our $15 million Series A offering—an opportunity to invest $50,000 or more in KIC Ventures and help bring viscoelastic disc replacement to the world
 

Tesla Moved Beyond Engines. AxioMed Moves Beyond Fusion.

Tesla revolutionized the auto industry by eliminating the internal combustion engine. AxioMed is bringing 10x technology to spine surgery by eliminating moving mechanical parts from disc replacements and avoiding fusions with pedicle screws, cages, and bone grafts.

 

Instead of rigidly fusing the spine, AxioMed’s viscoelastic total disc replacement mimics the function of a healthy natural disc, restoring movement rather than eliminating it.

For patients, this means:

✅ Better mobility – Maintains natural spinal motion, unlike fusion.

✅ Less pain – Reduces long-term complications associated with rigid implants.

✅ No mechanical parts – A single-piece viscoelastic design with no metal-on-metal articulation.

 

This is “The Road LESS™ Travelled,” an approach that follows the REP LESS™ philosophy: Restore function, Early intervention and Preserve anatomy.  As the only viscoelastic disc replacement poised to disrupt traditional spinal fusion methods, AxioMed is uniquely positioned to lead the $20+ billion global spine market toward a future of natural spine motion and improved patient outcomes.

 

The time is now to invest in bringing AxioMed to the U.S. market and preparing for a public offering.


 

AxioMed: A Market 10x Technology Advancement Opportunity

Just as Tesla pioneered the electric vehicle market, AxioMed is pioneering the viscoelastic disc replacement market. Traditional spine companies are equivalent to Ford and GM—locked into established technologies like pedicle screws and rods. While these companies generate billions, they continue to grow through acquisitions and make incremental improvements rather than develop truly advanced technology.

 

Tesla removed the engine. AxioMed removed mechanical discs and pedicle screws, cages and bone graft for fusion.

Unlike traditional disc replacements, AxioMed’s viscoelastic disc replacement moves beyond mechanical parts to mimic a natural disc, restoring movement and improving patient outcomes.

 

Over $90 million has been raised to bring AxioMed to this pivotal stage, supported by 10+ years of clinical data demonstrating zero device failures. Now, we are closing the final $10 million of our $15 million Series A offering—an opportunity to invest $50,000 or more in KIC Ventures and help bring viscoelastic disc replacement to the world.


 

Unparalleled Value Creation

In 2023, Tesla sold just 1.81 million vehicles—far fewer than GM’s 6.2 million and Ford’s 4.4 million—yet Tesla’s market cap dwarfs theirs.

 

The reason? Tesla leads the future.

 

Similarly, AxioMed’s value will not be limited by the number of discs sold—it will be defined by our ability to redefine spine surgery and lead the shift to motion preservation.

  • AxioMed is the only viscoelastic total disc replacement with over 10 years of clinical data and zero device failures.

  • FDA approval for our anterior lumbar disc is expected in 2025.

  • With U.S. commercialization, AxioMed is positioned to unlock a multi-billion-dollar opportunity.


 

Why Invest Now?

Whether you are an existing investor or considering AxioMed for the first time, this is a pivotal moment to take part in a transformative opportunity.

 

We are raising $15 million in our Series A round to fund:

✔ Manufacturing and global commercialization of the anterior lumbar disc.

✔ Advancing IDE studies for AxioMed’s lateral lumbar and multilevel cervical discs.

✔ Developing the AxioMedX Smart Disc for real-time patient feedback.

 

By investing now, you are not only helping bring AxioMed’s groundbreaking technology to market but also positioning yourself for significant value creation as we prepare for a potential public offering.

 

The success of Tesla illustrates the power of backing a 10x advancement in technology at the right time. AxioMed represents a similar unique, limited, and timely opportunity to transform the future of spine surgery.


 

For Existing Investors

We thank you for your continued belief in AxioMed. Your support has brought us to this critical stage, and we invite you to strengthen your stake during this pivotal round. By reinvesting now, you are amplifying your share in AxioMed’s future success as we move toward commercialization, FDA approval, and a public offering.

 

For New Investors

For the first time, we are opening KIC Ventures to investors outside our founding team. By investing in AxioMed through KIC Ventures, you gain equity in a company with a diversified portfolio—providing multiple exit opportunities as we continue to build value across our innovative platforms.


 

How to Invest

KIC Ventures has partnered with IRA Club to allow investors to use tax-advantaged retirement funds to invest in AxioMed. This enables tax-free growth within your portfolio.

 

📅 Schedule a call with Aditya Humad, CFO, directly at https://calendly.com/kicventurescfo to learn more about investing with retirement funds.


 

Timing Is Everything

Tesla capitalized on a global shift to electric vehicles—and its investors were rewarded.

AxioMed is poised to lead the global shift to motion-preserving spine surgery.

 

This is a rare opportunity to be part of an industry transformation. Whether you’re an early investor looking to increase your stake or new to AxioMed, now is the time to take action.

 

We welcome the opportunity to discuss further. Let us know a convenient time to connect.


Warm regards,

Kingsley R Chin, MD, MBA

CEO KIC Ventures

6550 NE Federal HWY Suite 510 Fort Lauderdale FL USA  33308


About The Author

Kingsley R. Chin, MD, MBA, is a board-certified Professor of Orthopedic Spine Surgery and an honors graduate of Harvard Medical School and the Harvard Combined Orthopedic Residency Program. He completed his spine fellowship with Dr. Henry H. Bohlman and served as Chief of Spine Surgery at the University of Pennsylvania. In addition to his clinical expertise, Dr. Chin completed the executive leadership program at Harvard Business School and is the CEO of KIC Ventures, where he leads innovations in spine surgery technology and investment.


For more information, please visit www.KICVentures.com or contact Investor@KICVentures.com


This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. Past performance is not indicative of future results.


References:

108 views0 comments

Comments


bottom of page